Clinical-stage Biotechnology - Immunology and Inflammatory Disorders
Strategic Profile
The lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two separate Phase 2 clinical studies: TibuSURE for systemic sclerosis and TibuSHIELD for hidradenitis suppurativa. TibuSHIELD is expanding enrollment to 225 participants with topline data expected in Q4 2026, while TibuSURE is enrolling with topline data expected in H1 2027.
Cyborg Score Rationale
The company highlighted two potentially transformative readouts expected over the next 18 months with tibulizumab as a lead bispecific program. With $139.0 million in cash and cash equivalents as of September 30, 2025, the company expects to fund planned operations through 2027. Recent leadership change adds execution risk.
Top Insights
Sandeep Kulkarni, M.D. was named CEO effective January 21, 2026; he co-founded and led Tourmaline Bio through its acquisition by Novartis.
Tibulizumab is an engineered bispecific dual-antagonist antibody that neutralizes interleukin (IL)-17A and B-cell activating factor.
Additional product candidates crebankitug (ZB-168) and torudokimab (ZB-880) have completed Phase 1/1b studies and are being evaluated across various autoimmune conditions.
The company is focused on tibulizumab for hidradenitis suppurativa and systemic sclerosis with expanded enrollment in 2026.
Named Competitors
Ixekizumab — IL-17A antagonist approved for hidradenitis suppurativa
TNX-650 (BAFF inhibitor) — BAFF pathway modulation for systemic sclerosis
Belimumab — BAFF antagonist for lupus and systemic sclerosis
Recent Developments
(January 2026) New CEO appointment: Sandeep Kulkarni replaces Robert Lisicki
(2026) TibuSHIELD HS trial enrollment expanded to 225 participants; topline data expected Q4 2026
(2026) TibuSURE SSc study enrolling; topline data expected H1 2027
Open the full interactive Zura Bio Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.